ArticleFrontiers in medicine2025
Multimorbidity of hidradenitis suppurativa: a cross-sectional population-based study of its associated comorbidities.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Decreased HDL-C in hidradenitis suppurativa: association with systemic inflammatory phenotype and implications for risk stratification.Lipids in health and disease · 2026Article
- Risk of irritable bowel syndrome in patients with hidradenitis suppurativa: a global-federated, multicenter cohort study.Scientific reports · 2026Observational
- Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disorder associated with significant physical and psychological burden. While individual comorbidities have been described in prior studies, a comprehensive analysis of all chronic conditions associated with HS in a large population-based cohort is lacking. Objectives: To determine the prevalence of hidradenitis suppurativa in a large-scale, population-based study, to describe its comorbidities, and to analyze which diseases are associated with the presence of hidradenitis. Methods: Retrospective cross-sectional observational study based on the clinical information contained in the electronic health records from the individuals of the EpiChron Cohort (Aragón, Spain) with a diagnosis of hidradenitis suppurativa (1,003 individuals from all ages and sexes) in 2019. We analyzed the prevalence of chronic comorbidities and used logistic regression models adjusted for age, sex and comorbidities to calculate the likelihood of occurrence of each of the comorbidities with a prevalence ≥1% based on the presence of hidradenitis. We used a cut-off point for statistical significance of Results: The prevalence of hidradenitis suppurativa was 0.10%, and it was more prevalent in women (0.12% vs. 0.08%). The most frequent chronic comorbidities were disorders of lipid metabolism (27.8%), hypertension (19.7%), and anxiety disorders (18.7%). The conditions most associated with hidradenitis were (odds ratio; 95% confidence interval) skin and subcutaneous tissue infections (3.32; 2.56-4.30), diseases of white blood cells (2.11; 1.44-3.07), and schizophrenia and other psychotic disorders (2.17; 1.16-4.06), among others. Conclusion: HS is associated with a high burden of multimorbidity, encompassing metabolic, neuropsychiatric, musculoskeletal, and infectious conditions. These findings underscore the need for integrated and multidisciplinary management strategies. Further longitudinal research is warranted to explore causal relationships and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.